Free Trial

Mineralys Therapeutics Q3 2024 Earnings Report

Mineralys Therapeutics logo
$10.52 -0.02 (-0.19%)
As of 03/7/2025 04:00 PM Eastern

Mineralys Therapeutics EPS Results

Actual EPS
-$1.13
Consensus EPS
-$0.83
Beat/Miss
Missed by -$0.30
One Year Ago EPS
-$0.57

Mineralys Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mineralys Therapeutics Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Remove Ads

Mineralys Therapeutics Earnings Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Mineralys Therapeutics, Inc. (MLYS) Gets a Buy from Goldman Sachs
See More Mineralys Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mineralys Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mineralys Therapeutics and other key companies, straight to your email.

About Mineralys Therapeutics

Mineralys Therapeutics (NASDAQ:MLYS), a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

View Mineralys Therapeutics Profile

More Earnings Resources from MarketBeat